STEPHEN DAVIS - 15 Oct 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
CEO, Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
15 Oct 2022
Net transactions value
-$44,331
Form type
4
Filing time
18 Oct 2022, 21:16:18 UTC
Previous filing
02 Sep 2022
Next filing
20 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +5,938 +7.8% 81,813 15 Oct 2022 Direct F1
transaction ACAD Common Stock Sale $44,331 -2,804 -3.4% $15.81 79,009 15 Oct 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -5,938 -100% $0.000000* 0 15 Oct 2022 Common Stock 5,938 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3 The restricted stock units vest in four equal annual installments beginning 10/15/19.